# SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

> **NCT07182721** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 48 (estimated)

## Conditions studied

- HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer
- SKB264
- Inetetamab

## Interventions

- **DRUG:** SKB264 Plus Inetetamab

## Key facts

- **NCT ID:** NCT07182721
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-02-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182721, "SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07182721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*